Damani A Piggott1, Ravi Varadhan2, Shruti H Mehta3, Todd T Brown4, Huifen Li5, Jeremy D Walston5, Sean X Leng5, Gregory D Kirk6. 1. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. Department of Epidemiology, Johns Hopkins University School of Public Health, Baltimore, Maryland. dpiggot1@jhmi.edu. 2. Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland. 3. Department of Epidemiology, Johns Hopkins University School of Public Health, Baltimore, Maryland. 4. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. Department of Epidemiology, Johns Hopkins University School of Public Health, Baltimore, Maryland. 5. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. 6. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. Department of Epidemiology, Johns Hopkins University School of Public Health, Baltimore, Maryland. Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Abstract
BACKGROUND: Serum markers of inflammation increase with age and have been strongly associated with adverse clinical outcomes among both HIV-infected and uninfected adults. Yet, limited data exist on the predictive and clinical utility of aggregate measures of inflammation. This study sought to evaluate the relationship of a recently validated aggregate inflammatory index with frailty and mortality among aging HIV-infected and uninfected injection drug users. METHODS: Frailty was assessed among HIV-infected and uninfected participants in the AIDS Linked to the IntraVenous Experience (ALIVE) cohort study using the five Fried phenotypic criteria: weight loss, exhaustion, low physical activity, decreased grip strength, and slow gait. The aggregate inflammatory index was constructed from serum measures of interleukin-6 and soluble tumor necrosis factor-α receptor-1. Multinomial logistic regression was used to assess the relationship of frailty with inflammation. Cox proportional hazards models were used to estimate risk for all-cause mortality. RESULTS: Among 1,326 subjects, the median age was 48 years and 29% were HIV-infected. Adjusting for sociodemographics, comorbidity, and HIV status, frailty was significantly associated with each standard deviation increase in log interleukin-6 (odds ratio 1.33; 95% CI, 1.09-1.61), log tumor necrosis factor-α receptor-1 (odds ratio 1.25; 95% CI, 1.04-1.51) and inflammatory index score (odds ratio 1.39; 95% CI, 1.14-1.68). Adjusting for sociodemographics, comorbidity, HIV status, and frailty, the inflammatory index score was independently associated with increased mortality (HR 1.65; 95% CI, 1.44-1.89). CONCLUSION: A recently validated, simple, biologically informed inflammatory index is independently associated with frailty and mortality risk among aging HIV-infected and uninfected injection drug users.
BACKGROUND: Serum markers of inflammation increase with age and have been strongly associated with adverse clinical outcomes among both HIV-infected and uninfected adults. Yet, limited data exist on the predictive and clinical utility of aggregate measures of inflammation. This study sought to evaluate the relationship of a recently validated aggregate inflammatory index with frailty and mortality among aging HIV-infected and uninfected injection drug users. METHODS: Frailty was assessed among HIV-infected and uninfected participants in the AIDS Linked to the IntraVenous Experience (ALIVE) cohort study using the five Fried phenotypic criteria: weight loss, exhaustion, low physical activity, decreased grip strength, and slow gait. The aggregate inflammatory index was constructed from serum measures of interleukin-6 and soluble tumor necrosis factor-α receptor-1. Multinomial logistic regression was used to assess the relationship of frailty with inflammation. Cox proportional hazards models were used to estimate risk for all-cause mortality. RESULTS: Among 1,326 subjects, the median age was 48 years and 29% were HIV-infected. Adjusting for sociodemographics, comorbidity, and HIV status, frailty was significantly associated with each standard deviation increase in log interleukin-6 (odds ratio 1.33; 95% CI, 1.09-1.61), log tumor necrosis factor-α receptor-1 (odds ratio 1.25; 95% CI, 1.04-1.51) and inflammatory index score (odds ratio 1.39; 95% CI, 1.14-1.68). Adjusting for sociodemographics, comorbidity, HIV status, and frailty, the inflammatory index score was independently associated with increased mortality (HR 1.65; 95% CI, 1.44-1.89). CONCLUSION: A recently validated, simple, biologically informed inflammatory index is independently associated with frailty and mortality risk among aging HIV-infected and uninfected injection drug users.
Authors: Linda P Fried; Luigi Ferrucci; Jonathan Darer; Jeff D Williamson; Gerard Anderson Journal: J Gerontol A Biol Sci Med Sci Date: 2004-03 Impact factor: 6.053
Authors: Jeremy Walston; Evan C Hadley; Luigi Ferrucci; Jack M Guralnik; Anne B Newman; Stephanie A Studenski; William B Ershler; Tamara Harris; Linda P Fried Journal: J Am Geriatr Soc Date: 2006-06 Impact factor: 5.562
Authors: Ravi Kavasery; Noya Galai; Jacquie Astemborski; Gregory M Lucas; David D Celentano; Gregory D Kirk; Shruti H Mehta Journal: J Acquir Immune Defic Syndr Date: 2009-04-01 Impact factor: 3.731
Authors: Nur F Onen; Abayomi Agbebi; Enbal Shacham; Kate E Stamm; Alev R Onen; E Turner Overton Journal: J Infect Date: 2009-08-23 Impact factor: 6.072
Authors: Loic Desquilbet; Lisa P Jacobson; Linda P Fried; John P Phair; Beth D Jamieson; Marcy Holloway; Joseph B Margolick Journal: J Gerontol A Biol Sci Med Sci Date: 2007-11 Impact factor: 6.053
Authors: Anne B Newman; Michael C Sachs; Alice M Arnold; Linda P Fried; Richard Kronmal; Mary Cushman; Bruce M Psaty; Tamara B Harris; John A Robbins; Gregory L Burke; Lewis H Kuller; Thomas Lumley Journal: J Gerontol A Biol Sci Med Sci Date: 2009-09-01 Impact factor: 6.053
Authors: Lewis H Kuller; Russell Tracy; Waldo Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Jacqueline Neuhaus; Daniel Nixon; Nicholas I Paton; James D Neaton Journal: PLoS Med Date: 2008-10-21 Impact factor: 11.069
Authors: Ruth E Hubbard; M Sinead O'Mahony; George M Savva; Brian L Calver; Ken W Woodhouse Journal: J Cell Mol Med Date: 2009-03-06 Impact factor: 5.310
Authors: Kellie L Hawkins; Long Zhang; Derek K Ng; Keri N Althoff; Frank J Palella; Lawrence A Kingsley; Lisa P Jacobson; Joseph B Margolick; Jordan E Lake; Todd T Brown; Kristine M Erlandson Journal: AIDS Date: 2018-06-19 Impact factor: 4.177
Authors: Triin Umbleja; Todd T Brown; Edgar T Overton; Heather J Ribaudo; Jennifer A Schrack; Kathleen V Fitch; Pamela S Douglas; Steven K Grinspoon; Sarah Henn; Roberto C Arduino; Benigno Rodriguez; Constance A Benson; Kristine M Erlandson Journal: J Infect Dis Date: 2020-07-09 Impact factor: 5.226
Authors: Kristine M Erlandson; Derek K Ng; Lisa P Jacobson; Joseph B Margolick; Adrian S Dobs; Frank J Palella; Jordan E Lake; Hanhvy Bui; Lawrence Kingsley; Todd T Brown Journal: J Infect Dis Date: 2017-01-15 Impact factor: 5.226
Authors: Kristine M Erlandson; Suzanne Fiorillo; Fadzai Masawi; Ann Scherzinger; Grace A McComsey; Jordan E Lake; James H Stein; Judith S Currier; Todd T Brown Journal: AIDS Date: 2017-08-24 Impact factor: 4.177
Authors: Deanna Saylor; Anupama Kumar; Gertrude Nakigozi; Aggrey Anok; James Batte; Alice Kisakye; Richard Mayanja; Noeline Nakasujja; Kevin R Robertson; Ronald H Gray; Maria J Wawer; Carlos A Pardo; Ned Sacktor Journal: J Neurovirol Date: 2019-06-04 Impact factor: 2.643
Authors: Mara A McAdams-DeMarco; Hao Ying; Alvin G Thomas; Fatima Warsame; Ashton A Shaffer; Christine E Haugen; Jacqueline M Garonzik-Wang; Niraj M Desai; Ravi Varadhan; Jeremy Walston; Silas P Norman; Dorry L Segev Journal: Transplantation Date: 2018-10 Impact factor: 4.939
Authors: Amy C Justice; Kristine M Erlandson; Peter W Hunt; Alan Landay; Paolo Miotti; Russell P Tracy Journal: J Infect Dis Date: 2018-01-30 Impact factor: 5.226